Skip to content

The Effect of Dexmedetomidine Nasal Administration on Postoperative Cognitive Function in Elderly Patients Undergoing Laparoscopic Surgery

The Effect of Dexmedetomidine Nasal Administration on Postoperative Cognitive Function in Elderly Patients Undergoing Laparoscopic Surgery

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600120827
Enrollment
Unknown
Registered
2026-03-20
Start date
2026-03-21
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Group A:Nasal administration of dexmedetomidine+butorphanol tartrate group
Group B:Physiological saline placebo+butorphanol tartrate group
Group D:Physiological saline placebo+sufentanil group
Group C:Dexmedetomidine administered via nasal route+sufentanil group

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 65 years old; 2. There was no cognitive impairment before surgery (preoperative Montreal Cognitive Assessment Scale (MoCA) score >=26 points); 1.Mini Mental State Examination (MMSE) score >= 23 points; 3.The patient's physical classification is from grade I to grade III. According to the American Society of Anesthesiologists Physical Status Classification (ASA), the patient is physically healthy, has good development and nutrition, and has normal organ function; 4.Laparoscopic surgery with a planned duration of = 2 hours (including but not limited to gastric cancer radical surgery, colorectal cancer radical surgery, renal cancer radical surgery, etc.); 5. Research participants or legal representatives sign a written informed consent form;

Exclusion criteria

Exclusion criteria: 1.Merge nasal anatomical abnormalities or active nasal diseases (such as nasal polyps, chronic rhinitis, etc.); 2. Previous diagnosis of neurological/psychiatric disorders or neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease, epilepsy, etc.); 3. Uncontrolled severe cardiovascular disease (including but not limited to: systolic blood pressure = 180 mmHg and/or diastolic blood pressure = 110 mmHg, degree III or above atrioventricular block, sick sinus syndrome, symptomatic arrhythmia, etc.); 4.Moderate to severe damage to liver and kidney function (Child Pugh grade = B or eGFR4 weeks); 7.Allergic to butorphanol tartrate or contraindications to opioid use;

Design outcomes

Primary

MeasureTime frame
The incidence of POCD;

Secondary

MeasureTime frame
Postoperative pain score (NRS score) and adverse reactions such as PONV;Surgical duration (record the total time from skin incision to incision closure) and anesthesia duration;Measurement of inflammatory markers: serum IL-1, IL-6, IL-10, TNF - a;MMSE score and MoCA score;Hemodynamics and BIS values;

Countries

China

Contacts

Public ContactSun DeFeng

The First Affiliated Hospital of Dalian Medical University

sdf-yl@163.com+86 411 8363 5963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026